Based on the initial data generated in the Phase 1b trial, we believe that pociredir has the potential to increase fetal hemoglobin to levels that could ameliorate symptoms of sickle cell disease.
The webcast of the fireside chat will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A ...